印度疫情持续失控 中国疫苗股国药(01099.HK)复星医药(02196.HK)逆市续涨逾8.5%-13%破顶
印度新冠疫情持续失控,反观中国疫苗受到更多国家认可。相关股疫情股逆市续涨,尤其是复星医药(02196.HK)四连涨屡探顶,今天股价更突破2018年3月所创纪录高位54.4元後,午後升幅扩大至13.5%,报56元,成交仍有1,183万股。国药(01099.HK)股价也升破上周所创52周高位24.8元,最高见26.5元,现造26.2元,续升8.7%,成交增至1,668万股。
不过,已七连升的康希诺生物-B(06185.HK)今早股价平开,曾升至394.6元,暂受制今年2月所创纪录高位,掉头回吐低见380元,现造383.2元,回吐1.5%。
印度疫情持续恶化,新增单日确诊病例36.81万宗,连续第12天单日新增确诊人数超过30万宗。世卫警告,印度疫情危机可能会「发生在任何地方」。事实上,中国部分城市已检出印度变异毒株,香港也出现首例本地感染南非变种病毒,更多国家开始批准中国疫苗,最新是印尼批准使用国药疫苗,埃及和孟加拉近日也刚批准科兴和国药疫苗。此外,世卫可能於两周内认证中国疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.